Open Access Critical Evidence Review

Glycemic variability: clinical applications and new research perspectives

The analyzed study describes how continuous glucose monitoring makes visible fluctuations not summarized by HbA1c alone and proposes metrics to measure them. Independent studies confirm the utility of the coefficient of variation and other indicators, especially for hypoglycemia. Standardization remains incomplete; sensors and metrics can produce different results in practice.

Cite this article
Moscati, M. (2026). Glycemic variability: clinical applications and new research perspectives. Life Science Hub Journal. DOI: 10.5281/zenodo.24256858. https://lifesciencehub.info/en/glycemic-variability-clinical-applications-and-new-research-perspectives
LIFE Science Hub - Journal of Science · 2026 / Nov

DOI 10.5281/zenodo.24256858

Article history
Dates
  • Published 13/11/2026
  • Updated 15/11/2026
Revisions
  1. v1.0 — 13/11/2026 Initial publication of the article.
  2. v1.1 — 15/11/2026 Editorial update of content, sources or references.

LIFE Science Hub keeps a record of every published version of the article to ensure editorial transparency. Future revisions will appear here.

Continuous glucose monitor beside scientific still life and flowing wave forms, illustrating glucose variability and hidden glycemic swings beyond HbA1c.
CGM sensors and abstract graphs show how glycemic variability reveals fluctuations and the risk of hypoglycemia beyond HbA1c alone.

ABSTRACT

The study analyzed is a narrative review dedicated to glycemic variability, i.e., blood glucose fluctuations throughout the day and between different days. The objective was to describe the indicators obtainable from continuous glucose monitoring and their potential clinical and research use. In the available material, consisting only of the abstract, the authors report that variability increases from prediabetes to type 2 diabetes and is even greater in type 1 diabetes; they also note a correlation between the coefficient of variation and the risk of hypoglycemia.

In paragraph 3.1, “Glycemic variability,” of “The Choice to Live in Health or Illness” by Dr. A. Colonnese and R. Panzironi, the publication contributes primarily to explaining that HbA1c and mean blood glucose do not describe all daily glucose fluctuations and that continuous monitoring allows for the calculation of different parameters, such as standard deviation, coefficient of variation, MAGE, MODD, CONGA, and HBGI. Independent studies confirm that HbA1c may not adequately represent the individual glycemic profile and that the coefficient of variation is associated with a higher frequency of hypoglycemia. However, it remains important to interpret the values within the clinical context and using comparable measurement tools.

Analyzed study

Glucose Variability: A Review of Clinical Applications and Research Developments

Rodbard D

Diabetes technology & therapeutics, 2018

DOI: 10.1089/dia.2018.0092

PMID: 29916742

The research question was how to usefully define and measure glycemic variability using data from continuous glucose monitoring. The underlying hypothesis is that average glycemia, and therefore also glycated hemoglobin or HbA1c, is not enough on its own to represent daily glucose trends: two people can have a similar average but very different fluctuations.

The publication is relevant to the book's section because it describes the role of continuous glucose monitoring in making visible spikes, rapid drops, episodes of hypoglycemia, and differences between days that a single measurement or an average value cannot show. It also examines the main mathematical metrics used to synthesize this data.

As it is a review, the study does not test a new hypothesis in a single cohort of participants and cannot demonstrate that a specific metric improves clinical outcomes. Its main contribution is conceptual and methodological: it clarifies which aspects of glycemic oscillations are described by the different indicators and why their interpretation requires an appropriate clinical context.

Materials and methods of the original study

The publication is a review, meaning it is a summary of scientific literature rather than an experimental study conducted on a new group of people. In the available abstract alone, the authors discuss metrics of glycemic variability obtained primarily from continuous glucose monitoring records.

Among the indicators described are the standard deviation or SD, which expresses how much values are dispersed relative to their mean, and the coefficient of variation or CV, which relates this dispersion to the mean glycemia. Also reported are MAGE, an indicator of the amplitude of major glycemic excursions; MODD, a measure of the differences between values recorded at the same time on consecutive days; CONGA, an index of oscillations over predetermined time intervals; and HBGI, an index that summarizes exposure to high glucose values.

This information is not provided in the available material: bibliographic search strategy, databases consulted, period of included publications, study selection criteria, method for assessing the quality of evidence, and data extraction process. For this reason, it is not possible to determine from the available material whether the review was systematic or to quantify the number of studies examined.

Results

The key finding is that glycemic variability does not coincide with mean glycemia. In simple terms, an average may appear acceptable even when actual values alternate between significant spikes and rapid drops. According to the abstract, variability increases progressively from prediabetes to advanced type 2 diabetes and is higher in type 1 diabetes.

The authors report that the coefficient of variation is correlated with the risk of hypoglycemia, i.e., glucose values that are too low. The direction of the association indicated is therefore clear: greater variability, expressed by a higher CV, is accompanied by a higher risk of hypoglycemia. The abstract does not report numerical correlation values, confidence intervals, P-values, or the characteristics of the populations from which these observations are derived.

The standard deviation is described as strongly correlated with numerous other indicators, including interquartile range, MAGE, MODD, and Average Daily Risk Range. The practical significance is that different formulas can capture, at least in part, the same general phenomenon of glucose instability, while focusing on different aspects: the amplitude of spikes, the speed of oscillations, or the repeatability of the profile over subsequent days.

The paper also notes that graphical representations by time of day, day of the week, and percentage of time spent in specific glycemic ranges provide clinically useful information. However, from the abstract alone, it is not possible to know which results derive from individual studies, nor to quantitatively compare the performance of the different metrics.

Interpretation

For the reader, the essential message is that HbA1c and mean glycemia primarily describe the average level of glucose exposure, while continuous monitoring adds information regarding the stability or instability of that level. This difference is relevant because episodes of hyperglycemia and hypoglycemia can cancel each other out in the average, despite being very different in a person's daily life.

The narrative segment documented directly by the publication subject to the Evidence Review is: continuous glucose monitoring → calculation of different metrics → description of oscillations that do not emerge from the glycemic average or HbA1c alone. In particular, SD and CV describe the overall dispersion of values; MAGE focuses on the widest excursions; MODD evaluates how the profile changes between consecutive days; CONGA considers variations within a specific interval; HBGI is oriented toward the risk component linked to high values.

The reported association between a higher CV and an increased risk of hypoglycemia is biologically and clinically plausible, but it does not mean that the CV is a cause of hypoglycemia. The coefficient of variation is an indicator of glycemic profile instability and can help identify situations in which low episodes are more frequent. The publication, being a narrative review and not a clinical intervention, does not demonstrate that reducing a single metric automatically improves individual prognosis.

Independent confirming evidence

Initial confirmation of the first part of the narrative concerns the limitation of interpreting HbA1c as a complete snapshot of an individual's glycemic control. Beck and colleagues analyzed continuous glucose monitoring data and laboratory HbA1c from 387 participants across three randomized trials. For the same HbA1c value, they observed a wide range of estimated mean glucose: for example, with an HbA1c of 7%, the estimated range was 128–190 mg/dL. This result does not directly measure all metrics of variability, but it confirms that a single HbA1c value does not uniquely identify a person's glycemic profile [1].

The relationship between glycemic fluctuations and hypoglycemia was directly evaluated by Monnier and colleagues in 376 people with diabetes undergoing continuous monitoring. The CV, calculated as the standard deviation divided by the mean glucose and multiplied by 100, increased from the group treated with diet and/or insulin-sensitizing drugs to those with type 1 diabetes. In groups treated with sulfonylureas or insulin, and in type 1 diabetes, the frequency of hypoglycemia was higher when the CV exceeded 36% compared to when it was equal to or less than 36%. This observational study therefore supports the direction reported in the review: a higher CV is associated with more hypoglycemia, without proving that the CV is the cause [2].

A second retrospective study evaluated 60 people with type 1 diabetes and 100 with type 2 diabetes, who underwent continuous monitoring for 3–6 days and capillary blood glucose recordings. In type 1 diabetes, the frequency of hypoglycemia was higher compared to type 2 diabetes, 53.3% versus 24%, and the CV obtained from continuous monitoring was higher, 40.1% versus 29.4%. HbA1c was a weak predictor of hypoglycemia, while the CV from continuous monitoring discriminated risk well in type 1 diabetes, with an area under the curve of 0.88. The area under the curve here indicates a good ability of the index to distinguish between those who do and do not experience hypoglycemia in the studied sample [3].

Overall, these independent publications support the choice to supplement HbA1c with dynamic information obtained from continuous monitoring. The confirmation is more robust regarding the descriptive value of monitoring and the association between high variability and hypoglycemia, while it is less direct for every single formula cited in the book's paragraph. SD, CV, MAGE, MODD, CONGA, and HBGI are not, in fact, perfectly overlapping measures and must be selected based on the clinical or research question.

Conflicting evidence

No directly conflicting evidence of sufficient relevance has been identified; this does not prove the absence of contrary results. However, there is significant evidence of a methodological limitation: values derived from continuous monitoring can depend on the device and even the individual sensor used.

In an analysis of 20 people with type 1 diabetes, each of whom wore two Dexcom G5 sensors and two FreeStyle Libre sensors in parallel for 14 days, Pleus and colleagues compared time in different glycemic ranges, glucose management indicator, and CV. Significant differences emerged both between different systems and between sensors of the same model. Among different systems, the 75th percentile of absolute differences was 5.0 percentage points for time below 70 mg/dL, 9.2 percentage points for time above 180 mg/dL, and 0.42 percentage points for the glucose management indicator [4].

This observation does not deny that continuous monitoring makes glycemic oscillations visible. However, it indicates that a value for CV, time in range, or other metrics should not be interpreted as an absolute measure that is perfectly interchangeable between devices. The sample was small, included exclusively people with type 1 diabetes, and the duration was limited to 14 days; the result therefore calls for caution, consistency in the instrument used for longitudinal comparisons, and standardization of methods.

Summary table of evidence

The table distinguishes the publication subject to the Evidence Review from the independent research used to confirm or contextualize the narrative of the paragraph.

Reference Study type Population or model Main result Direction of evidence Strength of evidence
Original study Narrative review Literature on continuous glucose monitoring Describes metrics of glycemic variability and reports that a higher CV is correlated with a greater risk of hypoglycemia. biologically consistent evidence moderate
[1] Descriptive analysis of data from randomized trials 387 participants from three randomized trials The same HbA1c value corresponded to a wide range of estimated average glucose. indirect confirmation moderate
[2] Observational 376 people with diabetes undergoing continuous monitoring CV greater than 36% associated with higher frequency of hypoglycemia, especially in groups treated with insulin. direct confirmation moderate
[3] Retrospective observational 60 people with type 1 diabetes and 100 with type 2 diabetes In type 1 diabetes, the CV from continuous monitoring effectively discriminated the presence of hypoglycemia; HbA1c was a weak predictor. direct confirmation moderate
[4] Post hoc technical comparison analysis 20 people with type 1 diabetes; four sensors worn in parallel for 14 days Continuous monitoring metrics, including CV, varied between devices and between sensors of the same model. discordant evidence low

Confirmation of the evidence

Claim in the book

In section 3.1 of “The Choice to Live in Health or Illness” by Dr. A. Colonnese and R. Panzironi, the relevant statement is that glycemic variability allows for the capture of aspects of metabolic regulation not described by HbA1c alone, and that continuous glucose monitoring allows for the derivation of various mathematical parameters to describe the stability or instability of glycemic values.

HbA1c and average glycemia → partial information on the individual profile → continuous glucose monitoring → oscillation metrics → identification of instability and risk of hypoglycemia

The publication subject to the Evidence Review was used in the book to support the following passage: continuous glucose monitoring allows for the observation of oscillations not synthesized by average glycemia or HbA1c alone and for their quantification through indicators such as SD, CV, MAGE, MODD, CONGA, and HBGI.

The correspondence between the original publication and the paragraph is methodologically and clinically consistent. The analyzed study illustrates that glycemia is not just an average, but a trend over time composed of peaks, drops, and day-to-day differences. The analysis by Beck and colleagues confirms that HbA1c does not uniquely identify an individual's glycemic profile: the same HbA1c can correspond to a wide range of mean glycemia [1]. This reinforces the premise of the paragraph, without proving on its own that two people necessarily have the same HbA1c and different variability.

The most specific passage of the review, namely the use of CV as an index associated with hypoglycemia, is confirmed by two independent studies. In 376 people with diabetes, a CV greater than 36% was associated with a higher frequency of hypoglycemia in groups treated with sulfonylureas, insulin, and in type 1 diabetes [2]. In a further sample of 160 people, the CV derived from continuous monitoring showed a good ability to discriminate hypoglycemia in type 1 diabetes, while HbA1c alone was a weak indicator [3].

The narrative, however, requires a clarification: the metrics are not interchangeable, and estimates can change depending on the device and sensor. Parallel comparison between monitoring systems has shown potentially relevant differences in the values obtained [4]. Therefore, continuous monitoring complements HbA1c, but it does not automatically replace clinical judgment nor does it make any single indicator a universal measure.

Overall level of confirmation

MODERATE CONFIRMATION

The central point is supported by the publication that is the subject of the Evidence Review and by independent studies that confirm both the informational limitations of HbA1c alone and the association between high CV and a higher frequency of hypoglycemia. The confirmation remains moderate because the available evidence is largely observational or descriptive, and the metrics also depend on the monitoring system used.

Conclusions

The analyzed publication consistently supports the idea that glycemic variability represents a distinct dimension from mean glycemia and HbA1c alone. Its most relevant contribution to the book chapter concerns the utility of continuous monitoring to visualize and quantify fluctuations that average indicators do not describe. Independent evidence moderately confirms that HbA1c does not always summarize an individual's glycemic profile and that a higher CV is associated with a greater frequency of hypoglycemia. A cautious interpretation of the values remains necessary, as metrics have different functions and may vary depending on the device used.

Overall assessment

The narrative of the paragraph is moderately supported. It is reasonably well supported that continuous monitoring adds dynamic information not contained in HbA1c alone and that high variability, especially a high CV, is associated with more hypoglycemia. Limitations regarding standardization, comparability between sensors, and the demonstration of long-term clinical outcomes remain.

References

[1] The Fallacy of Average: How Using HbA1c Alone to Assess Glycemic Control Can Be Misleading

Beck RW, Connor CG, Mullen DM, Wesley DM, Bergenstal RM, 2017

Diabetes Care

[2] Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes

Monnier L, Colette C, Wojtusciszyn A, Dejager S, Renard E, Molinari N, et al., 2017

Diabetes Care

[3] Beyond HbA1c: Comparing Glycemic Variability and Glycemic Indices in Predicting Hypoglycemia in Type 1 and Type 2 Diabetes

Rama Chandran S, Tay WL, Lye WK, Lim LL, Ratnasingam J, Tan ATB, et al., 2018

Diabetes Technology & Therapeutics

[4] Time in Specific Glucose Ranges, Glucose Management Indicator, and Glycemic Variability: Impact of Continuous Glucose Monitoring (CGM) System Model and Sensor on CGM Metrics

Pleus S, Kamecke U, Waldenmaier D, Link M, Zschornack E, Jendrike N, et al., 2021

Journal of Diabetes Science and Technology

Editorial note

Artificial Intelligence was used solely as a tool to support editorial and documentary work. All content, interpretations, bibliographic citations and conclusions have been verified, reviewed and approved by the author, who assumes full scientific responsibility for them.

The manuscript was also subject to independent peer review prior to publication.

To ensure maximum transparency, the article's complete history — including the dates of submission, review, acceptance and publication, as well as information on the peer review process — is available on the dedicated Article History page.